Responses to olutasidenib in patients with AML who have failed treatment with venetoclax

Responses to olutasidenib in patients with AML who have failed treatment with venetoclax

01:22 |

Related Videos

iStopMM: the psychological effects of MGUS screening and changes to clinical presentation of myeloma

5:11

iStopMM: the psychological effects of MGUS screening and changes to clinical presentation of myeloma

Welcome to the Video Journal of Hematology & Hematological Oncology 🎥🩸

3:08

Welcome to the Video Journal of Hematology & Hematological Oncology 🎥🩸

Frontline treatment for CLL: the changing paradigm

1:31

Frontline treatment for CLL: the changing paradigm

The future of CLL treatment: aiming for long-lasting remission

1:42

The future of CLL treatment: aiming for long-lasting remission

The tests that are needed to make a definitive diagnosis of CLL

2:59

The tests that are needed to make a definitive diagnosis of CLL

Biomarker-guided treatment of CLL in the chemo-free era

6:54

Biomarker-guided treatment of CLL in the chemo-free era

Personalizing the timing of SCT in patients with myelofibrosis

2:13

Personalizing the timing of SCT in patients with myelofibrosis

A model including CD49d expression to predict outcomes in patients with CLL treated with ibrutinib

2:55

A model including CD49d expression to predict outcomes in patients with CLL treated with ibrutinib

The use of outpatient cilta-cel in the treatment of multiple myeloma

1:36

The use of outpatient cilta-cel in the treatment of multiple myeloma

Trials of interest in newly diagnosed myeloma presented at IMS 2024

3:48

Trials of interest in newly diagnosed myeloma presented at IMS 2024

The role of asparaginase in the treatment of ALL

3:02

The role of asparaginase in the treatment of ALL

Early detection and interception across hematological cancers

0:44

Early detection and interception across hematological cancers

Recommendations for biomarker analysis in CLL: updates from ERIC 2024

5:40

Recommendations for biomarker analysis in CLL: updates from ERIC 2024

Cardiotoxicity associated with MCL-1 inhibition for R/R hematologic malignancies

2:38

Cardiotoxicity associated with MCL-1 inhibition for R/R hematologic malignancies

Challenges in the treatment and management of ET and the need to improve therapeutic approaches

5:21

Challenges in the treatment and management of ET and the need to improve therapeutic approaches

Treatment-free remission after second-generation TKI treatment in CML

1:01

Treatment-free remission after second-generation TKI treatment in CML

Master class in transplantation and hematology: highlights

3:40

Master class in transplantation and hematology: highlights

Prognostic and predictive biomarkers in CLL and their potential in guiding treatment decisions

1:25

Prognostic and predictive biomarkers in CLL and their potential in guiding treatment decisions

The use of golcadomide in combination with R-CHOP for the treatment of aggressive B-cell lymphomas

1:38

The use of golcadomide in combination with R-CHOP for the treatment of aggressive B-cell lymphomas

Promising therapies under investigation in AL amyloidosis: anti-fibril agents & bispecifics

1:14

Promising therapies under investigation in AL amyloidosis: anti-fibril agents & bispecifics